Cargando…
Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries
BACKGROUND: Many people living with chronic HBV infection remain undiagnosed until later stages of disease. Increasing testing and treatment rates form part of the strategy to respond to the WHO goal of eliminating viral hepatitis as a public health threat by 2030. However, achieving these ambitious...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688395/ https://www.ncbi.nlm.nih.gov/pubmed/29143675 http://dx.doi.org/10.1186/s12879-017-2778-x |
_version_ | 1783279154170429440 |
---|---|
author | Nayagam, Shevanthi Sicuri, Elisa Lemoine, Maud Easterbrook, Philippa Conteh, Lesong Hallett, Timothy B. Thursz, Mark |
author_facet | Nayagam, Shevanthi Sicuri, Elisa Lemoine, Maud Easterbrook, Philippa Conteh, Lesong Hallett, Timothy B. Thursz, Mark |
author_sort | Nayagam, Shevanthi |
collection | PubMed |
description | BACKGROUND: Many people living with chronic HBV infection remain undiagnosed until later stages of disease. Increasing testing and treatment rates form part of the strategy to respond to the WHO goal of eliminating viral hepatitis as a public health threat by 2030. However, achieving these ambitious targets is dependent on finding effective and cost-effective methods of scale up strategies. The aim of this study was to undertake a narrative review of the literature on economic evaluations of testing and treatment for HBV infection, to help inform the development of the 2017 WHO Hepatitis Testing Guidelines. METHODS: We undertook a focussed literature review for economic evaluations on testing for HBV accompanied by antiviral treatment. The search was carried out in Pubmed and included only articles published after 2000 and written in English. We narratively synthesise the results and discuss the key drivers of cost-effectiveness and their applicability to low and middle-income countries (LMICs). RESULTS: Nine published studies were included in this review, only one of which was performed in a low or middle-income setting in West Africa. Eight studies were performed in high-income settings, seven among high risk groups and one among the general population. The studies were heterogeneous in many respects including the population and testing strategy under consideration, model structure and baselines parameters, willingness to pay thresholds and outcome measures used. However, most studies found HBV testing and treatment to be cost-effective, even at low HBsAg prevalence levels. CONCLUSIONS: Currently economic evaluations of HBV testing and treatment strategies in LMICs is lacking, therefore limiting the ability to provide formal recommendations on the basis of cost-effectiveness alone. Further implementation research is needed in order to help guide national policy planning. |
format | Online Article Text |
id | pubmed-5688395 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56883952017-11-21 Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries Nayagam, Shevanthi Sicuri, Elisa Lemoine, Maud Easterbrook, Philippa Conteh, Lesong Hallett, Timothy B. Thursz, Mark BMC Infect Dis Review BACKGROUND: Many people living with chronic HBV infection remain undiagnosed until later stages of disease. Increasing testing and treatment rates form part of the strategy to respond to the WHO goal of eliminating viral hepatitis as a public health threat by 2030. However, achieving these ambitious targets is dependent on finding effective and cost-effective methods of scale up strategies. The aim of this study was to undertake a narrative review of the literature on economic evaluations of testing and treatment for HBV infection, to help inform the development of the 2017 WHO Hepatitis Testing Guidelines. METHODS: We undertook a focussed literature review for economic evaluations on testing for HBV accompanied by antiviral treatment. The search was carried out in Pubmed and included only articles published after 2000 and written in English. We narratively synthesise the results and discuss the key drivers of cost-effectiveness and their applicability to low and middle-income countries (LMICs). RESULTS: Nine published studies were included in this review, only one of which was performed in a low or middle-income setting in West Africa. Eight studies were performed in high-income settings, seven among high risk groups and one among the general population. The studies were heterogeneous in many respects including the population and testing strategy under consideration, model structure and baselines parameters, willingness to pay thresholds and outcome measures used. However, most studies found HBV testing and treatment to be cost-effective, even at low HBsAg prevalence levels. CONCLUSIONS: Currently economic evaluations of HBV testing and treatment strategies in LMICs is lacking, therefore limiting the ability to provide formal recommendations on the basis of cost-effectiveness alone. Further implementation research is needed in order to help guide national policy planning. BioMed Central 2017-11-01 /pmc/articles/PMC5688395/ /pubmed/29143675 http://dx.doi.org/10.1186/s12879-017-2778-x Text en © World Health Organization. 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution IGO License (http://creativecommons.org/licenses/by/3.0/igo/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL. |
spellingShingle | Review Nayagam, Shevanthi Sicuri, Elisa Lemoine, Maud Easterbrook, Philippa Conteh, Lesong Hallett, Timothy B. Thursz, Mark Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries |
title | Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries |
title_full | Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries |
title_fullStr | Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries |
title_full_unstemmed | Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries |
title_short | Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries |
title_sort | economic evaluations of hbv testing and treatment strategies and applicability to low and middle-income countries |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688395/ https://www.ncbi.nlm.nih.gov/pubmed/29143675 http://dx.doi.org/10.1186/s12879-017-2778-x |
work_keys_str_mv | AT nayagamshevanthi economicevaluationsofhbvtestingandtreatmentstrategiesandapplicabilitytolowandmiddleincomecountries AT sicurielisa economicevaluationsofhbvtestingandtreatmentstrategiesandapplicabilitytolowandmiddleincomecountries AT lemoinemaud economicevaluationsofhbvtestingandtreatmentstrategiesandapplicabilitytolowandmiddleincomecountries AT easterbrookphilippa economicevaluationsofhbvtestingandtreatmentstrategiesandapplicabilitytolowandmiddleincomecountries AT contehlesong economicevaluationsofhbvtestingandtreatmentstrategiesandapplicabilitytolowandmiddleincomecountries AT halletttimothyb economicevaluationsofhbvtestingandtreatmentstrategiesandapplicabilitytolowandmiddleincomecountries AT thurszmark economicevaluationsofhbvtestingandtreatmentstrategiesandapplicabilitytolowandmiddleincomecountries |